Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium
· Overall Response Rate (ORR) has increased to 25% (local review RECIST 1.1) · Median time to progression continues to improve as data matures, now 5.1 months1 with >40% of patients still on treatment · Continued good safety and tolerability profile. Longest running patient still on treatment after ~17 months with sustained partial response Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today further improved clinical benefit with fostrox +